Skip to content

Ganaxolone

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator — NERVOUS SYSTEM

Also known as: CCD 1042, GNX, ztalmy

EMA approvedFDA approvedOrphan designationATC N03AX27

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ganaxolone is a drug in the Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class catalogued in DrugCentral. It was first approved by the FDA in 2022. Its mechanism of action is classified as GABA A Receptor Positive Modulators. DrugCentral lists 3 molecular targets, including GABRB1|GABRG2|GABRA2, GABRB1|GABRG2|GABRA3 and GABRA1|GABRB1|GABRG2. Recorded indications include Seizures associated with CDKL5 deficiency disorders.

  • Drug class: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator.
  • Mechanism of action: GABA A Receptor Positive Modulators.
  • Molecular targets: GABRB1|GABRG2|GABRA2, GABRB1|GABRG2|GABRA3 and GABRA1|GABRB1|GABRG2 (3 listed in DrugCentral).
  • Indications: Seizures associated with CDKL5 deficiency disorders.
  • ATC code: N03AX27 (Other antiepileptics).
  • Molecular formula: C22H36O2; molecular weight 332.53 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Seizures associated with CDKL5 deficiency disorders

Mechanism & targets

Mechanism of action (MoA)GABA A Receptor Positive Modulators
Established pharmacologic classNeuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

Molecular targets (3)

TargetGeneActionActivity
GABA A receptor alpha-2/beta-1/gamma-2GABRB1|GABRG2|GABRA2modulatorEC50 7.03
GABA A receptor alpha-3/beta-1/gamma-2GABRB1|GABRG2|GABRA3modulatorEC50 6.91
GABA A receptor alpha-1/beta-1/gamma-2GABRA1|GABRB1|GABRG2modulatorEC50 6.67

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2023-07-26EMA—Marinus Pharmaceuticals Emerald LimitedYes
2022-03-18FDA—MARINUS PHARMA INC

ATC classification

ATC codeTherapeutic hierarchy
N03AX27NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: CDKL5 · Testing Required
  • FDA label: CDKL5 · Testing Required
  • HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Change in seizure presentation199.9
Product dose omission issue101.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ganaxolone is on its molecule page.

Molecular formulaC22H36O2
Molecular weight332.53 g/mol
CAS number38398-32-2
InChIKeyPGTVWKLGGCQMBR-FLBATMFCSA-N
PubChem CID6918305
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@](C)(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ganaxolone used for?

DrugCentral lists the following indications for Ganaxolone: Seizures associated with CDKL5 deficiency disorders.

How does Ganaxolone work?

Ganaxolone is classified as GABA A Receptor Positive Modulators; its molecular targets in DrugCentral include GABRB1|GABRG2|GABRA2 (modulator), GABRB1|GABRG2|GABRA3 (modulator) and GABRA1|GABRB1|GABRG2 (modulator).

When was Ganaxolone first approved?

Ganaxolone was first approved by the FDA in 2022.

What drug class does Ganaxolone belong to?

Ganaxolone is in the Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator class.

What is the chemical formula of Ganaxolone?

Ganaxolone has the molecular formula C22H36O2 and a molecular weight of 332.53 g/mol.

Browse: all drugs starting with G · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2022-03-18
AgencyFDA
Targets3
Indications1
FormulaC22H36O2
DrugCentral ID5508
Interactive profile